Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Phase 1

Withdrawn

Conditions: Multiple Myeloma (MM)
B-cell Acute Lymphoblastic Leukemia (B-ALL)
Acute Myeloid Leukemia (AML)
B-cell Non-Hodgkin's Lymphoma (B-NHL)
T-Cell Leukemia/Lymphoma, Adult

Interventions: Biological: Autologous CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-08-24

Last Posted Date: 2023-03-01

Lead Sponsor: Shanghai Pudong Hospital

Registration Number: NCT05513612

Locations: 🇨🇳
Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center, Shanghai, Shanghai, China

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Paclitaxel
Drug: Ipatasertib
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2022-08-12

Last Posted Date: 2024-06-18

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 146

Registration Number: NCT05498896

Locations: 🇬🇧
Barts Health NHS Trust, London, United Kingdom

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Early Phase 1

Recruiting

Conditions: Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib
Other: Brexucabtagene Autoleucel
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2022-08-10

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05495464

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN

Phase 4

Recruiting

Conditions: Mycophenolate Mofetil
Cyclophosphamide
Lupus Nephritis

Interventions: Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil

First Posted Date: 2022-08-10

Last Posted Date: 2022-08-10

Lead Sponsor: Second Xiangya Hospital of Central South University

Target Recruit Count: 224

Registration Number: NCT05495893

Locations: 🇨🇳
the Second Xiangya Hospital of Central South University, Changsha, Hunan, China

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
TNBC - Triple-Negative Breast Cancer

Interventions: Drug: Toripalimab
Drug: Epirubicin
Procedure: High Intensity Focused Ultrasoun
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Nab-paclitaxel

First Posted Date: 2022-08-08

Last Posted Date: 2022-08-08

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 20

Registration Number: NCT05491694

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1

Recruiting

Conditions: Melanoma (Skin)
Triple-Negative Breast Cancer
Non-Small Cell Lung Cancer
Synovial Sarcoma
Myxoid Liposarcoma
Colorectal Cancer
Osteosarcoma
Sarcoma

Interventions: Drug: PeptiCRAd-1
Drug: Cyclophosphamide
Drug: Pembrolizumab

First Posted Date: 2022-08-08

Last Posted Date: 2024-12-27

Lead Sponsor: Valo Therapeutics Oy

Target Recruit Count: 15

Registration Number: NCT05492682

Locations: 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪
National Center for Tumor Diseases, Heidelberg, Germany
🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany